Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Accounts Payables (2016 - 2025)

Arcadia Biosciences' Accounts Payables history spans 12 years, with the latest figure at $1.5 million for Q4 2025.

  • For Q4 2025, Accounts Payables fell 31.07% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $1.5 million, down 31.07%, while the annual FY2025 figure was $1.5 million, 31.07% down from the prior year.
  • Accounts Payables reached $1.5 million in Q4 2025 per RKDA's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.2 million in Q2 2021 to a low of $905000.0 in Q4 2022.
  • Average Accounts Payables over 5 years is $2.5 million, with a median of $2.1 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: plummeted 65.63% in 2021, then soared 111.05% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $1.4 million in 2021, then crashed by 35.86% to $905000.0 in 2022, then soared by 111.05% to $1.9 million in 2023, then increased by 10.37% to $2.1 million in 2024, then tumbled by 31.07% to $1.5 million in 2025.
  • Per Business Quant, the three most recent readings for RKDA's Accounts Payables are $1.5 million (Q4 2025), $2.0 million (Q3 2025), and $1.6 million (Q2 2025).